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Glutamate racemase (MurI) provides D-glutamate, a key building block in the peptidoglycan of the
bacterial cell wall. Besides having a crucial role in cell wall biosynthesis, MurI proteins from some
bacteria have been shown to act as an inhibitor of DNA gyrase. Mycobacterium tuberculosis
and Mycobacterium smegmatis MurI exhibit these dual characteristics. Here, we show that the
two activities of M. tuberculosis MurI are unlinked and independent of each other. The
racemization function of MurI is not essential for its gyrase-inhibitory property. MurI–DNA gyrase
interaction influences gyrase activity but has no effect on the racemization activity of MurI.
Overexpression of MurI in vivo provides resistance to the action of ciprofloxacin, suggesting the
importance of the interaction in gyrase modulation. We propose that the moonlighting activity
of MurI has evolved more recently than its racemase function, to play a transient yet important role
in gyrase modulation.
INTRODUCTION
The concept of the ‘one gene, one enzyme’ hypothesis,
originally proposed by Beadle and Tatum, and later
adapted to ‘one gene, one polypeptide’ (Kenez, 1973),
has undergone a major modification with the influx of a
vast body of information from multiple genomes. It is now
apparent that one gene does not necessarily encode only
one polypeptide with a single function. Cells employ
various strategies to increase protein functionality without
the burden of increasing the genome size. One of the
means is by evolving ‘moonlighting’ proteins that are able
to perform multiple, independent functions (Jeffery, 2003).
Moonlighting proteins arise from existing proteins by
recruiting existing binding sites for new functions, or by
modifying unused regions for a new purpose (Jeffery,
2003). These proteins are usually metabolic enzymes,
which in addition to catalysis can perform a second,
independent, non-catalytic function. Some can perform
both an enzymic and a secondary function simultaneously,
while others switch between two functions. However, not
all moonlighting proteins are enzymes (Jeffery, 1999).
Moonlighting enzymes can perform their multiple func-
tions by using either the same or distinct binding sites. The
same protein may perform two different functions when
located in different parts of a cell. PutA, an enzyme from
Escherichia coli, acts as a pyrroline-5-carboxylate proline
dehydrogenase when associated with the plasma membrane
of a cell. However, when it is free in the cytoplasm, it has
no enzymic activity, but instead binds DNA and acts as a
transcriptional repressor of proline-utilization genes (Lee
et al., 2003). Bacterial Cpn10, Cpn60 and Hsp70 are also
considered as examples of moonlighting proteins as they
have been reported to stimulate or inhibit the proin-
flammatory actions of myeloid cells and vascular endothe-
lial cells (Henderson, 2005). DegP (HtrA) is a conserved
extracytoplasmic E. coli heat-shock protein with protease
(proteolysis) and chaperone (refolding) activities (Lipinska
et al., 1990; Spiess et al., 1999). The protein can monitor
the folded state of a substrate protein and then degrade or
refold it. It also can switch between chaperone and protease
functions in a temperature-dependent fashion; increasing
the temperature causes an increase in the protease activity
(Lipinska et al., 1990; Spiess et al., 1999). In mammals,
phosphoglucose isomerase (PGI), a glycolytic enzyme, is
secreted by several cell types and moonlights as neuroleu-
kin (Faik et al., 1988), autocrine motility factor (AMF)
(Watanabe et al., 1996) and differentiation and maturation
mediator (DMM) (Xu et al., 1996).
Glutamate racemase (MurI) is an essential enzyme
involved in the cell wall biosynthesis pathway in bacteria.
It catalyses the interconversion of L-glutamate to
Abbreviations: AMF, autocrine motility factor; CD, circular dichroism;
PGI, phosphoglucose isomerase.
Three supplementary figures are available with the online version of this
paper.
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D-glutamate, an important building block in peptidogly-
can. In the recent past, besides the racemization function,
a few glutamate racemases have been shown to moonlight
as gyrase inhibitors. E. coli MurI was the first one to be
shown to inhibit gyrase but only in the presence of UDP-
N-acetylmuramyl-L-alanine, a peptidoglycan precursor
and an absolute activator for the racemase (Ashiuchi
et al., 2002). Subsequently, YrpC, one of the two
glutamate racemases from Bacillus subtilis, was shown to
influence the activity of DNA gyrase in precursor-
independent fashion (Ashiuchi et al., 2003). MurI from
Mycobacterium tuberculosis was shown to inhibit DNA
gyrase by preventing DNA-binding activity of the enzyme
(Sengupta et al., 2006). Gyrase inhibition thus seems to be
an additional property of these enzymes. The observed
bifunctionality of glutamate racemases poses several
questions. (a) Is the racemization function of MurI
necessary for its gyrase inhibition property, i.e. do the
two activities mutually influence each other or are they
completely independent? (b) Does MurI use the same
active site (like PGI described above), i.e. its racemization
active site, for gyrase inhibition? (c) What is the effect of
the presence of the racemization substrate, L/D-glutamate,
on its gyrase-inhibitory function? (d) Why would
glutamate racemase, an apparently unlinked enzyme that
is involved in cell wall biosynthesis, inhibit DNA gyrase,
an essential enzyme involved in the topological transac-
tions of DNA?
In the present study we demonstrate that racemization and
gyrase inhibition are two independent activities of M.
tuberculosis MurI. Using engineered mutants compromised
in the racemization function, we show that their gyrase
inhibition profiles remain unaffected. Moreover, when
expressed in vivo, both wild-type and the mutant MurI
result in a relaxed genome owing to their gyrase-inhibitory
abilities. More importantly, expression of M. tuberculosis
MurI in vivo confers resistance to the action of ciprofloxacin.
METHODS
Bacterial strains and plasmids. Escherichia coli strains DH5a and
BL26(DE3) were used for cloning and overexpression, respectively, of
Mycobacterium tuberculosis MurI mutants. The murI gene of
M. tuberculosis was mobilized in the pJAM2 vector (Triccas et al.,
1998) from the pET11d-murI construct (Sengupta et al., 2006) to
generate pJAM2-mtmurI. Mycobacterium smegmatis mc2155 was used
to express MurI in a mycobacterial system. Plasmids pBR322 and
pUC18 were used for the biochemical assays.
Enzyme and substrate preparation. E. coli DNA gyrase subunits
GyrA and GyrB were purified as described by Maxwell & Howells
(1999). M. smegmatis DNA gyrase was purified as described
previously (Manjunatha et al., 2002). Supercoiled pUC18 and
pBR322 were prepared by standard DNA purification protocols
(Sambrook et al., 1989).
Site-directed mutagenesis and purification of MurI mutants.
Active-site mutants of MurI were generated by site-directed
mutagenesis using the megaprimer-inverse PCR method (Kirsch &
Joly, 1998). For generation of the C75S and C185S mutants, a pET20b
construct harbouring the wild-type murI gene was used as template.
The T7 promoter primer was used as forward primer for the C75S
mutant and the T7 terminator primer was used as reverse primer for
the C185S mutant. Oligonucleotide primers carrying the mutant
codon were used as forward primer for the C185S mutant (59-
GCTCTACGCACTATCCACTG-39) and reverse primer for the C75S
mutant (59-GTTGCTAGCGATCACCAACGC-39). The megaprimers
thus generated were used as complementary primers for the second
round of PCR amplification. The plasmid harbouring the C75S
mutant and C185S primer were used for generating the double
mutant. The mutants were confirmed by generation or loss of
restriction sites and also by sequencing. The double mutant construct
was also mobilized in pJAM2 vector for in vivo studies. The MurI
mutants were overexpressed from pET20b constructs in E. coli
BL26(DE3). The proteins were purified as described previously
(Sengupta et al., 2006).
Racemization activity. The racemization activity of MurI was
assessed as described previously (Gallo & Knowles, 1993). MurI
samples were incubated in the presence of D-glutamate (Sigma) and
then rapidly heated to inactivate the enzyme and assayed for L-
glutamate (Sigma) using NAD+/L-glutamate dehydrogenase (Sigma)
(Sengupta et al., 2006). In another independent assay, varying
concentrations of MurI (wild-type, C75S, C185S and C75SC185S
double mutant) were incubated in the presence of either D- or L-
glutamate substrate (10 mM) in a buffer containing 10 mM Tris/HCl,
pH 8.0, and 4 mM b-mercaptoethanol at 30 uC for 30 min. The
reactions were stopped by heat inactivation and centrifuged at
13 000 r.p.m. for 10 min to remove any precipitate. The supernatant
was then taken and the ellipticity was measured at 204 nm using a CD
spectrophotometer. The ellipticity of L/D-glutamate alone was used as
a reference and change in the ellipticity was calculated by subtracting
the value obtained at the zero time point from the value obtained at
the final time point.
Gyrase assays. Supercoiling assays for DNA gyrase were carried out
at 37 uC with 300 ng relaxed pUC18 and 10 nM DNA gyrase from M.
smegmatis in supercoiling buffer [35 mM Tris/HCl pH 7.5, 5 mM
MgCl2, 25 mM potassium glutamate, 2 mM spermidine, 2 mM ATP,
50 mg BSA l21 and 90 mg yeast tRNA l21 in 5% (v/v) glycerol].
Relaxation assays were carried out with 150 nM E. coli gyrase using
supercoiled pBR322 as the substrate in the supercoiling buffer devoid
of ATP. In order to assess the effect of L/D-glutamate on MurI-
mediated inhibition of DNA gyrase, 100 mM of L-glutamate, D-
glutamate or potassium chloride was added in the supercoiling assay
buffer. The reactions were carried out either in the presence or
absence of MurI for 60 min at 37 uC and terminated with 0.6% (w/v)
SDS. The assay mixtures were resolved on 1% agarose gel in 40 mM
Tris/actetate buffer containing 1 mM EDTA.
Nucleoid staining. M. smegmatis cells harbouring pJAM2-murI
constructs (both wild-type and double mutant) were grown in
Middlebrook 7H9 medium at 37 uC to mid-exponential phase, then
induced with 2% (w/v) acetamide and grown for a further 6 h. In
another set, after growth to mid-exponential phase, M. smegmatis
cells were treated with novobiocin (10 mg ml21) for 3 h. Cells were
pre-fixed in PBS, 1% (v/v) Triton X-100 and 2% (v/v) toluene
solution and incubated overnight at 4 uC. This cell suspension was
spotted on a slide and excess solution was removed, followed by the
addition of 2 mg lysozyme ml21 (freshly prepared) and 10 min
incubation. Excess lysozyme was removed by repeated washes with
PBS. The slide was dried at room temperature, and then 10 ml poly-L-
lysine (Sigma) was spread over the sample followed by drying again to
fix all cells tightly to it. DAPI solution (49,6-diamidino-2-phenylin-
dole), which binds specifically to DNA, was dropped on the sample
and it was covered by a glass coverslip. The nucleoid structure of the
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cells was observed through a fluorescence microscope at 606
magnification.
In vivo cytotoxicity assays. The effect of MurI on the toxicity
caused by ciprofloxacin was tested by spotting various concentrations
of the drug on a lawn of M. smegmatis mc2155 containing either
pJAM2 vector or pJAM2-mtmurI constructs. M. smegmatis transfor-
mants were grown in Middlebrook 7H9 medium supplemented with
0.4% (w/v) glucose at 37 uC to mid-exponential phase and then 1%
(v/v) inocula were poured onto Middlebrook 7H9 soft agar plates
(0.8%, w/v agar) containing appropriate antibiotics. Equal volumes
(2 ml) of the drugs from stock solutions of various concentrations
were spotted on the lawn of cells and the diameters of the zones of
inhibition were measured.
RESULTS
DNA gyrase does not influence the racemization
function of MurI
In our previous studies we established the mechanism of
inhibition of DNA gyrase by MurI (Sengupta et al., 2006).
MurI from M. tuberculosis interacts with the GyrA subunit
of DNA gyrase, which is the primary DNA-binding subunit
of the holoenzyme, also responsible for DNA cleavage and
religation (Sengupta et al., 2006). The binding of MurI to
GyrA thus disturbs the DNA binding and affects catalytic
activity of the holoenzyme. We asked whether DNA gyrase
has any influence on MurI racemization activity. In order
to assess this reciprocal role, MurI was incubated with D-
glutamate in either the absence or presence of DNA gyrase,
and L-glutamate formed as a result of the racemization
reaction was measured by adding NAD+ and L-glutamate
dehydrogenase (GDH). GDH-mediated conversion from L-
glutamate to a-ketoglutarate resulted in the reduction of
NAD+ to NADH, which in turn led to an increase in
absorbance at 340 nm. As shown in Fig. 1, the racemization
activity of MurI remained unaffected upon inclusion of
DNA gyrase in the assay mixture. From these results we
conclude that the racemization activity of MurI is not
influenced by DNA gyrase.
Racemization substrates have no effect on gyrase
inhibition by MurI
Specific binding of MurI to the GyrA subunit prevents the
binding of DNA gyrase holoenzyme to DNA (Sengupta
et al., 2006). Thus, although protein–protein interaction is
necessary for gyrase inhibition, it was not clear whether the
racemization activity of MurI has any role in gyrase
inhibition. In the case of mammalian PGI, presence of
inhibitors or its natural substrates blocked its moonlighting
function as an autocrine receptor, thereby suggesting the
use of the same active site for both the activities (Watanabe
et al., 1996). Further, site-directed mutagenesis of active-
site residues needed for PGI activity impaired AMF activity
(Suzuki et al., 2002; Tanaka et al., 2002). On the other
hand, the moonlighting role of the electron-transport
protein cytochrome c in apoptosis is not affected by the
disruption of the normal function of the protein (Lim et al.,
2002). To test the scenario in MurI, we included the
racemization substrate (L-glutamate) in the gyrase inhibi-
tion assay. Standard gyrase assay buffer contains 25 mM L-
glutamate, which was omitted in this case and instead
100 mM of either L-glutamate (potassium salt) or pot-
assium chloride (control) was added. The gyrase-inhibitory
profile of MurI remained unaltered irrespective of the
presence of the racemization substrate in both the super-
coiling (Fig. 2a, compare lanes 3 and 4) and the relaxation
assay (Fig. 2b, compare lanes 3 and 5). Based on these
results, we infer that MurI probably uses two distinct non-
overlapping sites for its two functions; the two activities of
MurI seem to be unlinked and independent of each other.
MurI mutants compromised in the racemization
function retain gyrase-inhibition ability
The racemase reaction catalysed by MurI requires an initial
deprotonation of the substrate’s R-proton, followed by a
reprotonation on the opposite face of the resulting planar
anionic intermediate (Gallo et al., 1993). In the general
mechanism assumed for the reactions catalysed by the
pyridoxal 59-phosphate (PLP)-independent amino acid
racemases, two optimally located cysteines are considered
to act as catalytic acid/base residues in the two proton
transfers required to invert the amino acid’s stereochem-
istry (Fig. 3a) (Glavas & Tanner, 1999, 2001). Primary
sequence alignment of M. tuberculosis MurI with other
glutamate racemases shows two highly conserved signature
motifs and cysteine residues at 75 and 185 position emerge
as the putative catalytic residues (Supplementary Fig. S1,
available with the online version of this paper). These
residues were mutated to serine, as it had been shown
earlier that such mutations resulted in 1000-fold reduction
in the racemization activity of MurI from Lactobacillus
fermenti (Glavas & Tanner, 1999). In addition to single
point mutants, a double mutant was also generated where
both cysteines were changed to serines. Mutant MurI
proteins (C75S, C185S and C75SC185S double mutant)
were purified as described in Methods (Fig. 3b). The
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0
Fig. 1. Effect of DNA gyrase on racemization activity of MurI. The
racemization assay was carried out as described in Methods, in the
absence (&) and presence (g) of DNA gyrase. Reduction of NAD
to NADH during the course of the reaction was monitored by
measuring absorbance at 340 nm.
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racemization activities of these mutants were monitored by
CD spectroscopy. The mutants were defective in racemiza-
tion function (both L to D as well as D to L conversion) to a
varying degree and the double mutant (C75SC185S)
retained very low (less than 10%) racemization activity
(Fig. 3c, d). Next, the mutants were assessed for their
ability to inhibit gyrase. All the mutants exhibited similar
gyrase-inhibitory profiles, comparable to that of the wild-
type (Fig. 3e). Even the double mutant, which was highly
compromised in its racemization function (Fig. 3c, d),
retained its gyrase inhibition ability, comparable to the
wild-type enzyme (Fig. 3e, lane 6). From these results, we
conclude that the two activities of this bifunctional MurI
are unlinked and independent of each other.
Alterations in the nucleoid structures upon
overexpression of MurI
DNA gyrase is involved in the maintenance of the negative
supercoiling status of the genome. Since MurI inhibits
DNA gyrase activity, it might play a role in modulation of
the topological status of the genome. In order to assess this
property, we monitored the nucleoid status in M.
smegmatis cells after overexpression of MurI. Both the
wild-type and the double mutant forms of MurI were
overexpressed from pJAM2 constructs in M. smegmatis
(Supplementary Fig. S2). In a parallel experiment, M.
smegmatis cells were treated with another well-known
gyrase inhibitor, novobiocin, at a concentration which has
been shown to result in genomic relaxation (Unniraman &
Nagaraja, 1999). As shown in Fig. 4 and also
Supplementary Fig. S3, the nucleoids in bacteria over-
expressing MurI (wild-type as well as mutant) appeared to
be diffused and dispersed throughout the entire length of
the cell, resembling the nucleoid status observed in
novobiocin-treated cells. In contrast, the cells harbouring
the vector alone showed a rather compact nucleoid
structure at the mid-cell site. These results indicate that
both the wild-type and the mutant MurI were able to
inhibit the supercoiling activity of DNA gyrase in vivo.
These studies further corroborate the in vitro data showing
that the double mutant with a compromised racemization
activity still retained its gyrase inhibition ability in vivo,
resulting in the relaxed genomic status.
MurI protects the bacteria from the action of
ciprofloxacin
The above results establish that moonlighting function of
MurI in gyrase modulation has originated independent of its
racemization property.What would be the physiological basis
for evolution of such an unlinked property in a dedicated cell
wall precursor synthesizing enzyme? One possibility is that
interaction of MurI with gyrase protects it from the action of
other inhibitors. In order to address this, we spotted different
concentrations of ciprofloxacin on a lawn of M. smegmatis
cells overexpressing the wild-type or double mutant form of
MurI. The formation of a zone of inhibition and its size is
indicative of the sensitivity of the cells to ciprofloxacin.
Diameters of the zones of inhibition weremeasured (Table 1).
The reduced diameters of the zones of inhibition in the case
of MurI-overexpressing cells indicate that MurI expression
leads to increased resistance to ciprofloxacin. MurI reduced
the double strand breaks induced by ciprofloxacin in vitro
(Fig. 5). MurI did not provide protection against mitomycin
C, a general DNA-damaging agent, thereby ruling out the
possibility that the ciprofloxacin resistance might be due to
altered cell wall permeability (not shown). MurI-mediated
protection was thus specific to DNA damage caused by
trapped gyrase–DNA covalent complexes. The double
mutant compromised in its racemization function protected
against the action of ciprofloxacin in a similar manner to that
of wild-type enzyme.
Gyrase
MurI
L-Glu
KCl
–
–
–
–
+
–
–
+
+
+
–
+
+
+
+
–
+
–
+
–
1 2 3 4 5
(a)
Gyrase
MurI
L-Glu
KCl
–
–
–
–
+
–
–
+
+
+
–
+
+
–
+
–
+
+
+
–
1 2 3 4 5
(b)
Fig. 2. Inhibition of DNA gyrase activities by MurI in the presence
of racemization substrate. (a) Effect of presence of L-glutamate on
supercoiling activity of DNA gyrase. M. smegmatis DNA gyrase at
a concentration of 10 nM, with 1 mM of either BSA or MurI, was
used for the supercoiling reaction. Lanes: 1, relaxed pUC18 alone;
2, gyrase activity in the presence of BSA and 100 mM KCl; 3,
gyrase activity in the presence of MurI and 100 mM KCl; 4, gyrase
activity in the presence of MurI and 100 mM L-glutamate; 5, gyrase
activity in the presence of BSA and 100 mM L-glutamate. (b)
Relaxation activity of DNA gyrase. E. coli enzyme at a concentra-
tion of 150 nM was used. Lanes: 1, supercoiled pUC18 alone; 2,
DNA gyrase activity in the presence of BSA and 100 mM KCl; 3,
gyrase activity in the presence of MurI and 100 mM KCl; 4, gyrase
activity in the presence of BSA and 100 mM L-glutamate; 5,
gyrase activity in the presence of MurI and 100 mM L-glutamate.
All the assays were repeated at least three times. Representative
results are presented.
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DISCUSSION
In the present study, we have shown that the two activities
of MurI from M. tuberculosis, viz. racemization and gyrase
inhibition, are unlinked and independent of each other.
Using site-directed mutants compromised in the racemiza-
tion function, we have demonstrated that the racemization
activity is not required for the gyrase-modulatory role of
MurI. This also suggests that probably a different surface of
MurI, away from its active site, is involved in interacting
with gyrase. The existence of a glutamate racemase that
does not inhibit gyrase, i.e. Glr from B. subtilis (Ashiuchi
et al., 2003), provides further support in this regard, since
in Glr, the racemization domains are highly conserved and
similar to those found in glutamate racemases having
gyrase-inhibitory properties. M. tuberculosis MurI interacts
O
_
O
_
O
_
O
_
O
OOO O
OH
OHOH
H
SH HS
_
S
_
S
S
_
S
_
H
SH
C75
L-Glutamate D-GlutamateEnolate
intermediate
Isomerization
C185
C75 C185
C75 C185
C75 C185
HS
NH
+ 
3
NH
+ 
3
NH
+ 
3
(b)
kDa
97
66
44
29
14
1 2 3 4 5
Gyrase
MurI
BSA
–
–
–
+
–
+
+
WT
–
+
C75S
–
+
C185S
–
+
DM
–
1 2 3 4 5 6
100
(c)
(a)
50
WT
D-Glu to L-Glu conversion L-Glu to D-Glu conversion
C75S C185S DM
(e)
WT
C75S 
C185S 
DM
A
ct
iv
ity
 (%
)
100
(d)
50
WT C75S C185S DM
A
ct
iv
ity
 (%
)
Fig. 3. Analysis with site-directed mutants of M. tuberculosis MurI. (a) Proposed catalytic mechanism of glutamate racemase.
Conserved putative active-site cysteines (M. tuberculosis) are shown schematically. Isomerization of the enzyme is represented
proceeding through the fully deprotonated state. (b) SDS-PAGE profile of purified mutants of M. tuberculosis MurI. Lanes: 1,
size markers; 2, wild-type MurI; 3, C75S MurI; 4, C185S MurI; 5, C75SC185S MurI. (c, d) CD spectrometry showing the
comparative racemization activity of these mutants, i.e. L-glutamate to D-glutamate conversion and vice versa. MurI samples
(1 mM) were incubated in the presence of either D- or L-glutamate substrate (10 mM) in buffer as described in Methods at
30 6C for 30 min. The reactions were stopped and the change in ellipticity was measured at 204 nm using a CD
spectrophotometer. Activity obtained with the wild-type enzyme was taken as 100% and the relative percentage activities of the
mutants were then plotted. (e) DNA gyrase supercoiling assay with these mutants. DNA gyrase at a concentration of 10 nM,
with 1 mM of BSA or MurI, was used for the assay. Lanes: 1, relaxed pUC18; 2, gyrase with BSA; 3, gyrase with wild-type MurI;
4, gyrase with C75S MurI; 5, gyrase with C185S MurI; 6, gyrase with C75SC185S double mutant MurI.
S. Sengupta and others
2800 Microbiology 154
with the DNA-binding subunit of DNA gyrase, GyrA
(Sengupta et al., 2006). Its interaction with GyrA thus
perturbs the normal catalytic activity of the gyrase, which
involves DNA binding followed by cleavage and religation.
In contrast, the gyrase interaction surface on MurI does not
seem to overlap with the catalytic site of the latter.
The physiological significance of MurI-mediated gyrase
modulation is yet to be understood. By preventing the
DNA-binding activity of gyrase, it protects the enzyme against
the cytotoxic action of gyrase poisons such as ciprofloxacin.
These observations could indicate that MurI may function to
safeguard the essential housekeeping enzyme, DNA gyrase,
from gyrase-targeting poisons. Unlike in E. coli, addiction
modules which target DNA gyrase in mycobacteria have not
been characterized so far. Alternatively, under conditions
when gyrase activity needs to be kept under control, MurI
could be involved in sequestration of DNA gyrase away from
its site of action, thus serving as a ‘checkpoint’ coordinating
the cell division and DNA replication.
An alarming increase in the emergence of multidrug-resistant
strains ofM. tuberculosis has led to an active search for novel
drug targets. MurI is an attractive target for designing new
antibacterial drugs as it provides D-glutamate, an important
component for peptidoglycan biosynthesis (Lundqvist et al.,
2007). Overexpression of M. tuberculosis MurI in soluble
form and also in large quantities described here
pJAM2 vector
10 mg novobiocin ml
_1
pJAM2-mtmurI (DM)
pJAM2-mtmurI (WT)
pJAM2 vector
Bright-field DAPI fluorescence Overlay
Fig. 4. Overexpression of MurI results in
diffused and dispersed nucleoid structures.
Comparison of nucleoid structures in M.
smegmatis mc2155 cells harbouring either the
pJAM2 vector or pJAM2-mtmurI (wild-type,
WT) or pJAM2-mtmurI (double mutant, DM)
constructs induced with 2% acetamide. Single
bacterial cells have been enlarged from a group
of cells of similar phenotype. Novobiocin-
treated cells were used as positive control,
showing the relaxed diffused nucleoids of cells
treated with the coumarin class of gyrase
inhibitor. Left panels, bright-field images; middle
panels, fluorescent images showing the DAPI-
stained nucleoid; right panels, overlay of the two
images. Scale bars, 1 mm.
Table 1. MurI expression increases resistance to ciprofloxacin
Cultures of M. smegmatis harbouring either the vector pJAM2 or pJAM2-mtmurI constructs (wild-type or
double mutant) were grown in Middlebrook 7H9 broth to mid-exponential phase at 37 uC and then poured
onto soft agar plates to form a lawn. Different dilutions of ciprofloxacin were spotted and then the plates were
incubated for 3–4 days to get defined zones of inhibition.
Ciprofloxacin (mg) Zone of inhibition (mm)
pJAM2 vector pJAM2-mtmurI
(wild-type)
pJAM2-mtmurI
(double mutant)
0.5 10±0.4 6.5±0.2 6.2±0.3
0.45 7.5±0.3 5.5±0.6 5.7±0.2
0.4 5.5±0.5 3.5±0.7 4.1±0.4
0.35 3.5±0.4 1.5±0.3 1.7±0.6
0.3 2±0.2 – –
0.25 1±0.4 – –
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(Supplementary Fig. S2) would facilitate high-throughput
screening of antimycobacterial compounds targeting MurI.
Finally, why have enzymes like MurI evolved such a distinct
moonlighting activity? Multifunctional proteins, which are
mostly ubiquitous enzymes, have acquired some additional
functions over the long period of their existence. Several
enzymes appear to be much larger than what seems to be
necessary for performing a single function. They often have
large unused solvent-exposed areas and pockets on the
protein surface that could be modified to make additional
binding sites. As long as these additional functions do not
interfere with the original function of the protein, they might
benefit the cell by providing a competitive advantage during
evolution. By having multifunctional proteins, a cell has
fewer proteins to synthesize and, consequently, less DNA to
replicate, thereby saving a great deal of energy in growth and
reproduction (Jeffery, 1999, 2003). Moonlighting proteins
can also provide a means of coordinating or modulating
cellular activities as in the case of MurI. The increasing
number of proteins that are being found to moonlight adds
another level to cellular complexity and regulation.
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